Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 195 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Study Reinforces Treatment Idea for Cancer with Microsatellite Instability October 2, 2020 FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who... March 20, 2025 Microplastics Can Be Detected In Human Organ Tissue August 20, 2020 EMA Recommends Granting a Conditional Marketing Authorisation for Selumetinib April 30, 2021 Load more HOT NEWS Age and Frailty Should Be Considered Independently When Evaluating Potential Risk... How to Spend Time with Friends and Family Now that COVID... Maintenance Therapy with CC-486 Extends Survival of Adults with AML Predicting future breast cancer with precision
